Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
NCT04897958 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14417
Last updated 2023-07-27
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
Degarelix
Degarelix dispensing claim is used as the reference group.
- DRUG
-
Leuprolide
Leuprolide dispensing claim is used as the exposure group.
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-21
- Primary Completion
- 2021-08-01
- Completion
- 2021-08-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of Tadalafil After Radical Prostatectomy
NCT01026818 ·Status: COMPLETED ·Phase: PHASE4
-
Enhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes
NCT05898932 ·Status: RECRUITING
-
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
NCT03297398 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018
NCT00945490 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
NCT01139762 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)
NCT00918983 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
NCT00947882 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
NCT00651807 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
NCT00970632 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Effects of a Prostate Health Formulation
NCT02886832 ·Status: COMPLETED ·Phase: NA
-
High Risk Prostate Cancer Prevention Study
NCT01174953 ·Status: COMPLETED ·Phase: NA
-
Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.
NCT00527488 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS
NCT01589263 ·Status: COMPLETED ·Phase: PHASE2
-
Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH)
NCT01454349 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
NCT00435448 ·Status: TERMINATED ·Phase: PHASE3
-
Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy
NCT00201630 ·Status: UNKNOWN ·Phase: PHASE3
-
RELIEF Study: Real-world Evaluation of LUTS Interventions and Patient Experience During Follow-up
NCT05784558 ·Status: WITHDRAWN
-
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
NCT01846793 ·Status: COMPLETED ·Phase: PHASE3
-
Real World Data on Management of Male LUTS
NCT03075449 ·Status: COMPLETED
-
Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)
NCT00759135 ·Status: COMPLETED ·Phase: PHASE2
-
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
NCT04288427 ·Status: RECRUITING ·Phase: NA
-
Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy
NCT00737893 ·Status: COMPLETED ·Phase: PHASE2
-
Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence
NCT01390870 ·Status: COMPLETED
-
New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia
NCT06944145 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy
NCT01435954 ·Status: COMPLETED